Advertisement
TransCode Therapeutics Inc. (RNAZ)
TransCode Therapeutics Statistics
Share Statistics
TransCode Therapeutics has 23.34M shares outstanding. The number of shares has increased by 256.81% in one year.
Shares Outstanding | 23.34M |
Shares Change (YoY) | 256.81% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | 0.09% |
Shares Floating | 20.98M |
Failed to Deliver (FTD) Shares | 188.67K |
FTD / Avg. Volume | 2.61% |
Short Selling Information
The latest short interest is 1.04M, so 4.45% of the outstanding shares have been sold short.
Short Interest | 1.04M |
Short % of Shares Out | 4.45% |
Short % of Float | 4.45% |
Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -0.01. TransCode Therapeutics's PEG ratio is 0.
PE Ratio | 0 |
Forward PE | -0.01 |
PS Ratio | 0 |
Forward PS | 1 |
PB Ratio | -0.01 |
P/FCF Ratio | 0 |
PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for TransCode Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.56, with a Debt / Equity ratio of -0.02.
Current Ratio | 2.56 |
Quick Ratio | 2.56 |
Debt / Equity | -0.02 |
Debt / EBITDA | 0 |
Debt / FCF | 0 |
Interest Coverage | -584.07 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-2.4M |
Employee Count | 7 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -11.2% in the last 52 weeks. The beta is 1.52, so TransCode Therapeutics's price volatility has been higher than the market average.
Beta | 1.52 |
52-Week Price Change | -11.2% |
50-Day Moving Average | 0.26 |
200-Day Moving Average | 0.29 |
Relative Strength Index (RSI) | 57.58 |
Average Volume (20 Days) | 7.22M |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -15.66M |
Net Income | -16.79M |
EBITDA | -14.03M |
EBIT | -14.57M |
Earnings Per Share (EPS) | -47.14 |
Balance Sheet
The company has 5.81M in cash and 38.29K in debt, giving a net cash position of 5.77M.
Cash & Cash Equivalents | 5.81M |
Total Debt | 38.29K |
Net Cash | 5.77M |
Retained Earnings | -63.2M |
Total Assets | 7.29M |
Working Capital | 4.32M |
Cash Flow
In the last 12 months, operating cash flow was -13.34M and capital expenditures 0, giving a free cash flow of -13.34M.
Operating Cash Flow | -13.34M |
Capital Expenditures | 0 |
Free Cash Flow | -13.34M |
FCF Per Share | -37.45 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
RNAZ does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for RNAZ is $10, which is 2225.6% higher than the current price. The consensus rating is "Buy".
Price Target | $10 |
Price Target Difference | 2225.6% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on Dec 4, 2024. It was a backward split with a ratio of 1:33.
Last Split Date | Dec 4, 2024 |
Split Type | backward |
Split Ratio | 1:33 |
Scores
Altman Z-Score | -18.9 |
Piotroski F-Score | 2 |